(19)
(11) EP 2 666 475 A8

(12) CORRECTED EUROPEAN PATENT APPLICATION
published in accordance with Art. 153(4) EPC

(15) Correction information:
Corrected version no 1 (W1 A1)

(48) Corrigendum issued on:
19.03.2014 Bulletin 2014/12

(88) Date of publication A3:
27.11.2013 Bulletin 2013/48

(43) Date of publication:
27.11.2013 Bulletin 2013/48

(21) Application number: 12736336.4

(22) Date of filing: 20.01.2012
(51) International Patent Classification (IPC): 
A61K 38/22(2006.01)
A61P 17/14(2006.01)
A61K 45/00(2006.01)
A61P 37/08(2006.01)
(86) International application number:
PCT/JP2012/051272
(87) International publication number:
WO 2012/099258 (26.07.2012 Gazette 2012/30)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 21.01.2011 JP 2011011437

(71) Applicants:
  • Igisu Co., Ltd.
    Minato-ku, Tokyo 1050004 (JP)
  • Endo, Yori
    Aoba-ku Sendai-shi Miyagi 9800011 (JP)
  • Endo, Kyoko
    Aoba-ku Sendai-shi Miyagi 9800011 (JP)

(72) Inventor:
  • ENDO, Kyoko
    Miyagi 9800011 (JP)

(74) Representative: Zech, Stefan Markus et al
Meissner, Bolte & Partner GbR Postfach 86 06 24
81633 München
81633 München (DE)

   


(54) THERAPEUTIC AGENT FOR ALOPECIA


(57) The present invention addresses the problem of providing a novel therapeutic agent for alopecia which: is safe and effective against alopecia, particularly alopecia areata, male pattern baldness in men, male pattern baldness in women, female pattern baldness, postpartum alopecia, seborrheic alopecia, alopecia pityrodes, alopecia senilis, alopecia due to chemotherapeutic agents, and alopecia due to radiation exposure; is also effective for subjects who are resistant to minoxidil and finasteride treatments; and is free of side effects such as itching, irritation and feminization, has no contraindications, reduces dandruff, has a therapeutic effect on grey hair, and has no long-term loss in therapeutic effect on alopecia even when stopped. The means for solving this problem is a therapeutic agent for alopecia that uses a C-type natriuretic peptide (CNP) or a B-type natriuretic peptide (BNP), derivatives of these natriuretic peptides (NPs), chimeric peptides of these NPs or derivatives of these NPs as active ingredients.